13
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Have Norwegians tried psilocybin, and do they accept it as a medicine?

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Psilocybin is emerging as a promising therapeutic agent for a wide range of psychiatric conditions, and clinical trials on psilocybin-assisted treatment are forthcoming in Scandinavian countries. However, little is known about attitudes towards this psychedelic compound among the general public in Nordic countries. This might represent a confound, and reduce the validity of research findings or the overall feasibility of conducting high-quality clinical trials.

          Aims

          The main objective of this study is to address the knowledge gap surrounding use and attitudes towards psilocybin in Norway.

          Methods

          We asked a representative sample of the Norwegian population ( N = 1,078) if they have ever tried psilocybin and if they would be willing to do so as part of medical treatment. These questions were part of a larger online survey on a variety personal preferences and attitudes, and the survey was not presented as a study on psilocybin.

          Results

          Of the 1,078 respondents, 8% reported previous psilocybin use and 51% were willing to try psilocybin in medical treatment.

          Conclusions

          Psilocybin use is more common in Norway than the authors hypothesized, and the general public is relatively open to using psilocybin in a medical context. The latter is interpreted as promising with regards to the feasibility of conducting rigorous clinical trials on potential effects and side effects of psilocybin-assisted treatment in Norway.

          Related collections

          Author and article information

          Contributors
          Journal
          2054
          Journal of Psychedelic Studies
          JPS
          Akadémiai Kiadó (Budapest )
          2559-9283
          11 May 2021
          15 April 2021
          : 5
          : 1
          : 33-36
          Affiliations
          [1 ] Mind-Body Lab, Department of Psychology, University of Oslo , Norway
          [2 ] Department of Pain Management and Research, Division of Emergencies and Critical Care, Oslo University Hospital , Oslo, Norway
          [3 ] Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Norway
          [4 ] PsykForsk, Østfold Hospital Trust , Norway
          Author notes
          [* ]Corresponding author.E-mail: henrbors@ 123456uio.no
          Article
          10.1556/2054.2021.00167
          aa3c1dfc-a464-49a9-bc54-cc79c27b39cd
          © 2021 The Author(s)

          Open Access. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated.

          Page count
          Tables: 1, Equations: 0, References: 10, Pages: 04

          Evolutionary Biology,Medicine,Psychology,Educational research & Statistics,Social & Behavioral Sciences
          psilocybin,population study,mental health,psychedelic-assisted therapy

          Comments

          Comment on this article